ARCUTIS BIOTHERAPEUTICS, INC. Research and Development in Process
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Research and Development in Process of $29.63 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-28
- ARCUTIS BIOTHERAPEUTICS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development in process for fiscal 2022 was $29.63M.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development in process for fiscal 2021 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development in process for fiscal 2020 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $29.63M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $29.63M 10-Q · filed 2022-11-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |